Post-earnings recap
Reported
Thu, Aug 6, 2026
EPS actual
$1.34
EPS est.
$1.12
EPS surprise
+19.86%
1-day move
+0.67%
Globus Medical's earnings report showed a strong performance in EPS, exceeding expectations by nearly 20%. The stock reacted positively, increasing by 0.67%, indicating investor confidence in the company's profitability despite the lack of revenue data and guidance. The absence of additional commentary from management leaves some uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.34 | N/A | +19.86% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based solely on numerical results.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±27.8%
Globus Medical, Inc. (GMED) is a leading company in the health care equipment sector, specializing in innovative musculoskeletal solutions. With a market cap of $12 billion, it plays a crucial role in improving patient outcomes through advanced surgical technologies and products.
Last quarter
In Q1-2026, Globus Medical reported an EPS of $1.12, exceeding expectations by 22%. However, the stock declined by 4.65% the following day, indicating market skepticism despite the positive earnings surprise.
Management promises and guidance
EPS beat streak
5Q
EPS beat rate
88%
Avg EPS surprise
+16.59%
Avg 1-day reaction
-0.05%
Overall, investors are cautiously optimistic about GMED's upcoming earnings report, especially after the recent positive EPS surprises. However, concerns about revenue growth and market conditions may temper expectations.
Bull case
If GMED continues its trend of beating EPS estimates and shows strong revenue growth, it could signal robust demand for its products and lead to a significant stock price increase.
Bear case
Conversely, if the company fails to meet revenue expectations or shows signs of slowing growth, it could lead to a negative reaction from investors, especially given the recent stock performance.
Key metrics to watch
Earnings Per Share (EPS)
$1.12EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue Growth
N/ARevenue growth reflects the company's ability to expand its market presence and drive sales, which is vital for long-term success.
The print will turn on these.
Q1
What will the EPS be this quarter compared to the previous quarter's $1.12?
The market will closely watch EPS as a key indicator of profitability and growth momentum.
Q2
How will revenue growth compare to previous quarters, particularly in light of recent market conditions?
Revenue growth is crucial for assessing the company's ability to expand and maintain its competitive edge.
Why consensus could be wrong
The Street may be underestimating GMED's ability to sustain its growth trajectory despite market pressures, as evidenced by its consistent EPS beats.
Supporting evidence
GMED has an 88% EPS beat rate, indicating strong operational execution.
The options market reflects a higher implied move than historical averages, suggesting potential for a significant surprise.
Recent performance trends show resilience in demand for health care equipment.
Key risk
If revenue growth is significantly below expectations, it could challenge the current bullish sentiment.
Pre-commit to what would confirm each case.
This quarter's performance will hinge on the balance between maintaining profitability and achieving revenue growth amidst market challenges.
Bull confirmed if
An EPS of $1.20 or higher would confirm strong operational performance and investor confidence.
Bear confirmed if
An EPS below $1.00 would raise concerns about profitability and market demand.
What the market is pricing for the move.
Implied Move
±16.79%
Historical Avg
±1.5%
The options market is pricing in a significant potential move in either direction, suggesting heightened uncertainty ahead of the earnings report.
Options are pricing ±16.8% while GMED has averaged ±1.5% over the last 8 prints — setup is pricing rich.
ATM IV
0.4%
30d HV
42.1%
Smart-money positioning from the most recent 13F filings.
Institutional
92.23%
of float
Insider
0.61%
of float
Holders
788
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
10,806,724 sh · $797.0M
8.05%
2.9%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If GMED beats expectations, history suggests a potential stock increase of around 1.66% on the following day, confirming strong demand.
In line / cautious
An in-line report with cautious commentary could lead to muted stock movement as investors reassess growth prospects.
Miss
If the company misses expectations, history suggests a potential decline of about 1.33%, reflecting investor disappointment.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
1 buy·0 sells
Members
1
House only
Est. Notional
$15,001.00–$50,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Gross Margin
N/AGross margin indicates how efficiently the company is producing its products and managing costs, impacting overall profitability.
Jupiter Topco LLC
8,200,423 sh · $604.8M
6.11%
100.0%
Vanguard Capital Management LLC
5,107,532 sh · $376.7M
3.80%
1.5%
Vanguard Portfolio Management LLC
4,994,385 sh · $368.3M
3.72%
2.4%
Invesco Ltd.
4,309,771 sh · $317.8M
3.21%
-0.2%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net buying
Recent Transactions
Traded Aug 19, 2026 · disclosed Sep 10, 2026
$15,001.00–$50,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.